Literature DB >> 21779463

Targeting MYC-Regulated miRNAs to Combat Cancer.

Anna Frenzel1, Jakob Lovén, Marie Arsenian Henriksson.   

Abstract

The MYC protein controls many cellular processes, including proliferation, cell cycle progression, cell growth, metabolism, angiogenesis, differentiation, cell adhesion, and motility. This is primarily achieved through transcriptional regulation of large gene networks that ultimately results in activation or repression of target genes. Given its broad regulatory scope, the expression of the MYC gene itself needs to be tightly controlled. Deregulation of MYC expression promotes tumorigenesis and, not surprisingly, MYC is frequently activated in many different human cancers. Furthermore, these tumors become highly dependent on sustained MYC expression, while MYC inactivation results in desirable anticancer effects, such as cell death, differentiation, and/or senescence. Thus, MYC has emerged as an attractive target for cancer therapy. In addition to regulating protein-coding genes, MYC also governs the expression of microRNAs, many of which have important regulatory roles in cancer development and progression. Here we will discuss how MYC-regulated miRNAs could be exploited for therapeutic development for cancer.

Entities:  

Keywords:  MYC; cancer; differentiation; microRNA; targeted therapy

Year:  2010        PMID: 21779463      PMCID: PMC3092216          DOI: 10.1177/1947601910377488

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  118 in total

Review 1.  The Oscar-worthy role of Myc in apoptosis.

Authors:  Natalie Meyer; Sam S Kim; Linda Z Penn
Journal:  Semin Cancer Biol       Date:  2006-07-14       Impact factor: 15.707

Review 2.  Not miR-ly small RNAs: big potential for microRNAs in therapy.

Authors:  Tara M Love; Howell F Moffett; Carl D Novina
Journal:  J Allergy Clin Immunol       Date:  2008-02       Impact factor: 10.793

Review 3.  Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation.

Authors:  Anders Edsjö; Linda Holmquist; Sven Påhlman
Journal:  Semin Cancer Biol       Date:  2006-05-10       Impact factor: 15.707

4.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Authors:  Konstantinos J Mavrakis; Andrew L Wolfe; Elisa Oricchio; Teresa Palomero; Kim de Keersmaecker; Katherine McJunkin; Johannes Zuber; Taneisha James; Aly A Khan; Christina S Leslie; Joel S Parker; Patrick J Paddison; Wayne Tam; Adolfo Ferrando; Hans-Guido Wendel
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

5.  Transcriptional repression: the dark side of myc.

Authors:  Barbara Herkert; Martin Eilers
Journal:  Genes Cancer       Date:  2010-06

6.  MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Authors:  Jakob Lovén; Nikolay Zinin; Therese Wahlström; Inga Müller; Petter Brodin; Erik Fredlund; Ulf Ribacke; Andor Pivarcsi; Sven Påhlman; Marie Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 7.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

8.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

9.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

10.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  32 in total

1.  Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Guillermo N Armaiz-Peña; Lingegowda S Mangala; Fatma Valiyeva; Cristina Ivan; Sunila Pradeep; Ileabett M Echevarría-Vargas; Adrian Rivera-Reyes; Anil K Sood; Pablo E Vivas-Mejía
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

2.  Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters.

Authors:  Chui-Sun Yap; Abigail L Peterson; Gastone Castellani; John M Sedivy; Nicola Neretti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

3.  Myc: the beauty and the beast.

Authors:  Amanda R Wasylishen; Linda Z Penn
Journal:  Genes Cancer       Date:  2010-06

4.  Genome-Wide Analysis of c-MYC-Regulated mRNAs and miRNAs and c-MYC DNA-Binding by Next-Generation Sequencing.

Authors:  Rene Jackstadt; Markus Kaller; Antje Menssen; Heiko Hermeking
Journal:  Methods Mol Biol       Date:  2021

5.  MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Authors:  Ruth L Vinall; Alexandra Z Ripoll; Sisi Wang; Chong-Xian Pan; Ralph W deVere White
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

6.  Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.

Authors:  Arash Javeri; Massoud Ghaffarpour; Masoumeh Fakhr Taha; Massoud Houshmand
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

7.  MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression.

Authors:  Zichao Zhang; KyoungHyun Kim; Xiao Li; Myriam Moreno; Thad Sharp; Michael J Goodheart; Stephen Safe; Adam J Dupuy; Brad A Amendt
Journal:  Mol Cancer Ther       Date:  2014-04-30       Impact factor: 6.261

Review 8.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

Review 9.  Polycomb group proteins and MYC: the cancer connection.

Authors:  Leonidas Benetatos; George Vartholomatos; Eleftheria Hatzimichael
Journal:  Cell Mol Life Sci       Date:  2013-07-30       Impact factor: 9.261

10.  B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

Authors:  Shaoying Li; Adam C Seegmiller; Pei Lin; Xuan J Wang; Roberto N Miranda; Sharathkumar Bhagavathi; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2014-08-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.